The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
|
|
- Thomasine Sanders
- 5 years ago
- Views:
Transcription
1 The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall potential risks or benefits of a product which are based on an evaluation of an entire research program. Before prescribing any Takeda products, healthcare professionals should consult prescribing information for the product approved in their country.
2 2.0 SYNOPSIS Name of Sponsor: Takeda Global Research & Development Center, Inc. Name of Finished Product: Lu AA21004 Investigator: Stuart Harris, MD Publication Based on the Study: None Study Period: 14 July 2008 to 05 January 2009 OBJECTIVES Study Center: SeaView Research, Inc NW 7th St Miami, FL USA Phase of Development: Phase 1 Primary: The primary objective of this study was to evaluate the effects of Lu AA21004 relative to placebo on cardiac repolarization following multiple oral doses in healthy adult male subjects. Secondary: The secondary objectives of the study were as follows: To characterize the pharmacokinetic profiles of Lu AA21004 and its metabolites Lu AA34443 and Lu AA39835 associated with the 10 and 40 mg once daily (QD) doses in healthy adult male subjects. To evaluate the safety and tolerability of Lu AA and 40 mg QD in healthy adult male subjects. To establish assay sensitivity to the response in the QT/heart rate-corrected QT (QTc) interval following a single dose of 400 mg moxifloxacin in healthy adult male subjects. METHODS This was a phase 1, double-blind, randomized study featuring a 4-treatment parallel-group design to evaluate the effect of multiple doses of Lu AA21004 and a single dose of moxifloxacin on QTc intervals recorded in healthy adult male subjects. The study planned to enroll and randomize 340 male subjects, aged 18 to 45 years, inclusive, to 4 treatment groups (85 subjects per treatment group).
3 Sequence of Events for Each Treatment Group Screening Check- In Baseline Placebo Dosing Study Medications (1 or 2 or 3 or 4) (a) Days -28 to -3 Day -2 Day -1 Days 1-14 Days ECG PK + ECG PK confinement to study clinic Washout Final Assessment /ET Follow-up (b) Days Day 28 Day 44 Outpatient Visit Phone Call ECG=electrocardiogram; ET=early termination; PK=pharmacokinetics. (a) Study medications: (1) Lu AA mg QD, (2) Lu AA mg QD, (3) placebo, (4) placebo on Days 1 to 13 and moxifloxacin 400 mg on Day 14. (b) At 30 days following the last dose, a phone call was made to inquire about adverse events/serious adverse events (SAEs) and concomitant medications since final dose of study medication. The study consisted of Screening (Days -28 to -3), Check-in (Day -2), a Treatment Period (Day -1 and Days 1 to 14), Final Assessment/Early Termination (Day 28), and a follow-up phone call on Day 44. Subjects reported to the clinic on the morning of Day -2 (Check-in) and remained confined until the final pharmacokinetic blood sampling was completed on Day 22. Subjects returned to the clinic on the morning of Day 28 as an outpatient visit for the completion of the Final Assessment/Early Termination procedures. A follow-up phone call was made 30 days after administration of the last dose of study medication (Day 44). Number of Subjects (Planned and Analyzed): Planned: 340 subjects. Analyzed: Electrocardiogram (ECG) population 327 subjects; Pharmacokinetic population (excluding placebotreated subjects) 246 subjects; Safety population 340 subjects. Diagnosis and Main Criteria for Inclusion: To qualify for study participation, subjects must have been healthy males; aged 18 to 45 years, inclusive; weighing at least 50 kg and with a body mass index of 19 to 32 kg/m 2, inclusive; with a resting pulse and heart rate between 45 and 100 bpm; in good health as determined by the investigator per medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations (hematology, blood biochemistry, and urinalysis); testing negative for hepatitis B surface antigen and hepatitis C virus antibody; and willing to sign the informed consent form, and comply with the protocol requirements. Test Product, Dose and Mode of Administration, Lot Number: Drug Dose Form Route Lot No. Lu AA mg Overencapsulated tablet Oral E E01 Lundbeck tablet: Lu AA21004 placebo N/A Capsule Oral E E01 Avelox (moxifloxacin) 400 mg Tablet Oral BXC9481 N/A=not applicable. Duration of Treatment: The total duration of the study was approximately 72 days, consisting of Screening (Days -28 to -3), Check-in (Day -2), a Treatment Period (Day -1 and Days 1 to 14), Final Assessment/Early Termination (Day 28), and a follow-up phone call on Day 44.
4 Reference Therapy, Dose and Mode of Administration, Lot Number: None. Criteria for Evaluation: ECG: The following ECG parameters were derived: The largest time-matched, baseline-adjusted least squares (LS) means difference in QT/QTc intervals: QT, QT interval corrected by Fridericia formula (QTcF), QT interval corrected by Bazett s formula (QTcB), QT interval corrected by Framingham formula (QTcFm), QT interval corrected by individual linear formula (QTcNi[Linear]), and QT interval corrected by individual log-linear formula (QTcNi[Nonlinear]) between Lu AA21004 and placebo. Time-matched, baseline-adjusted LS means difference in the absolute ECG interval measurements (heart rate, PR and QRS intervals) between the treatments. Time-matched, baseline-adjusted LS means difference in average of 3 QT/QTc measurements around the time at which the maximum observed plasma concentration (Cmax) occurred (Tmax) (including Tmax) for Lu AA21004, Lu AA34443, and Lu AA39835 between Lu AA21004 and placebo group. The average of the 3 measurements for the placebo group was the corresponding time points to those that constituted the 3 measurements around Tmax for the Lu AA21004 group. The same corresponding time points were used at Baseline for both the Lu AA21004 and placebo groups. Number and percentage of subjects with absolute QTc intervals above 450, 480, and 500 ms and the number and percentage of subjects with increases from Baseline above 30 and 60 ms. Number and percentage of subjects with abnormal T-wave morphology and presence of U-waves (ECG). Outliers for heart rate, PR interval, and QRS duration. Pharmacokinetic: For each subject the following plasma pharmacokinetic parameters of Lu AA21004, its metabolites Lu AA34443 and Lu AA39835, and moxifloxacin were derived on Day 14 of each treatment group: Cmax, observed minimum plasma concentration (Cmin), time at which Cmax occurred (Tmax), area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC[0-24]), oral clearance (CL/F) for Lu AA21004 only, and apparent volume of distribution at steady state (Vss/F) for Lu AA Safety: Safety variables included adverse events, clinical laboratory test results (hematology, serum chemistry, and urinalysis), vital sign measurements, weight, physical examination results, and 12-lead ECG findings. Genotype Analysis: Subjects were genotyped for common cytochrome P450 (CYP) 2C9, CYP2C19, and CYP2D6 allelic variants associated with drug disposition. Statistical Methods: ECG Measures The following QT correction methods were used for ECG analysis: Mean QTcF: QT QTcF 3 RR (RR is expressed in units of seconds)
5 Mean QTcB: QT QTcB 2 RR (RR is expressed in units of seconds) Mean QTcFm: QTcFm QT 0.154(1 RR) (RR and QT expressed in units of seconds) An individual correction was generated by using the slope of each subject s predose QT/RR relationship to normalize the data to a zero correlation coefficient between QT and RR. The slope for correction was calculated from the algebraic constant from the line of best fit (LS) for the QT/RR relationship for all values of QT/RR from predose and baseline ECG for each subject, where the equation for the linear fit was in the form: QT=Intercept + slope RR The following formula for QT correction was used: QTcNi=QT + slope (1 RR) The planned primary endpoint for ECG analysis was the largest time-matched baseline-adjusted LS means difference for QTcNi between Lu AA21004 and placebo at posttreatment ECG collection times. The original raw ECG data consisting of triplicate measurements at each timepoint was averaged. The averaged values were used to derive corrected values of QTcNi as well as QTcF, QTcB, and QTcFm. The secondary endpoints for ECG analysis included the largest time-matched baseline-adjusted LS means difference in QT/QTc intervals (QT, QTcF, QTcB, and QTcFm) between Lu AA21004 and placebo at post treatment ECG collection times. An additional analysis using the heart-rate correction method of QTcNi (Nonlinear) (derived as QTcNi=QT/RR, where was obtained from the log[rr]) was performed. As a post-hoc analysis, the accuracy of each QTc method (QTcNi[Linear], QTcF, QTcB, QTcFm and QTcNi[Nonlinear] for heart rate correction was assessed using on-drug values. For this evaluation, each subject s QTc/RR slope on-drug was estimated and the average of the squared slopes was calculated. The QTc method that generated an average slope closest to zero (ie, a flat slope demonstrating no relation between RR and QTc) was deemed to be the most appropriate for heart rate correction. Mixed effects models with treatment, time, treatment-by-time interaction as fixed effects, baseline QT/QTc as covariate and repeated measure analysis with AR(1) covariance structure and subject as a random effect were used to model change from Baseline in QT/QTc on Day 14. Within the framework of the analyses of variance LS mean estimates and their corresponding 90% confidence intervals (CIs) of Lu AA21004 treatments to placebo difference were presented at each time of measurement on Day 14. To assess the assay sensitivity a 90% CI for the difference in LS means between moxifloxacin and placebo treatments was also presented. An analysis similar to the one described above was performed on QT/QTc based on the average of 3 measurements around Tmax for Lu AA21004, Lu AA34443, and Lu AA39835; this analysis included only the Lu AA21004 treatment groups and placebo. In addition the time-matched, baseline-adjusted LS means difference in the absolute ECG interval measurements (heart rate; PR and QRS intervals) between the treatments were analyzed. Categorical analysis of the number and percentage of subjects meeting threshold of QTc intervals is provided and the number and percent subjects of abnormal T-wave morphology and presence of U-waves (ECG). The number and percentage of subjects with absolute QTc interval>450 ms, 480 ms, and >500 ms and is provided for each treatment group. Similar summary information is provided for QT and QTc interval increases from Baseline of >30 ms and >60 ms. The percentage of subjects who show abnormal T and U waves was summarized by treatment. Outlier analysis was performed for PR interval, QRS duration, and heart rate.
6 Outlier analysis of the PR interval and the QRS duration for each treatment was performed by presenting the number and percentage of subjects who have a greater than 25% change from Baseline. Results were tabulated by treatment. In addition, the mean change and 2-sided 90% CI in PR and QRS intervals from placebo after baseline-adjustment was computed. Outlier analysis of heart rate for each treatment was performed by presenting the number and percentage of subjects who have a greater than 25% decrease from Baseline or a heart rate of less than 50 bpm (bradycardia) or a greater than 25% increase from Baseline or with a heart rate greater than 110 bpm (tachycardia). The relationship between Lu AA21004 plasma concentrations and time-matched placebo and baseline-corrected QT/QTc measurements was assessed as an exploratory analysis using a mixed effects modeling approach with linear terms alone and also with a linear and quadratic term of plasma and its 2-sided 90% CI at Cmax of Lu AA21004 was provided. Plots of change from baseline QT/QTc at each time point versus plasma concentration were provided for each treatment group. Pharmacokinetic Measures: Descriptive statistics (number of subjects, mean, SD, percent coefficient of variation, minimum, and maximum) is provided at each sampling time for plasma concentrations and plasma pharmacokinetic parameters of Lu AA21004, Lu AA34443, Lu AA39835, and moxifloxacin. Assessments of the achievement of steady-state conditions for plasma concentrations of Lu AA21004, Lu AA34443, and Lu AA39835 were also performed. Safety Measures: All safety assessments, including adverse events, clinical laboratory evaluations, vital signs,12-lead ECG results, and physical examination was summarized with descriptive statistics, where appropriate, and presented in the data listings. SUMMARY OF RESULTS Subject Disposition: A total of 340 men (mean age of 32.6 years) were enrolled into the study and equally randomized to 1 of the 4 treatment groups: placebo only, Lu AA mg, Lu AA mg, and placebo/moxifloxacin (placebo on Days 1 to 13 and moxifloxacin 400 mg on Day 14). Of these, 328 subjects (96.5%) completed the study and 12 subjects (3.5%) were prematurely discontinued and did not complete the study as planned (2 subjects placebo only, 4 subjects Lu AA mg, 3 subjects Lu AA mg, and 3 subjects placebo/moxifloxacin). The reasons for subject withdrawal included: adverse events (8 subjects, 2 subjects in each treatment group), withdrawal of consent (5 subjects, 1 subject Lu AA mg, 2 subjects Lu AA mg, and 2 subjects placebo/moxifloxacin), and other reasons (2 subjects, 1 subject Lu AA mg and 1 subject Lu AA mg). Pharmacodynamic (QTc) Results: Summary of Baseline-Adjusted, Time-matched Change for Heart Rate and QT/QTc Interval Results The mean time-matched, baseline-adjusted change in heart rate observed on Day 14 in the placebo and moxifloxacin 400 mg treatment groups ranged from 5.5 (at 1 hour postdose) to 8.9 bpm (at 12 hours postdose) and 7.5 (at 23.5 hours postdose) to 11.1 bpm (at 12 hours postdose), respectively. The mean time-matched, baseline-adjusted changes in heart rate in the Lu AA mg and Lu AA mg treatment groups ranged from 2.9 (at 8 hours postdose) to 5.6 bpm (at 3 hours postdose) and from 1.3 (at 1 hour postdose) to 5.1 bpm (at 7 hours postdose), respectively. This heart rate increase observed after multiple doses of Lu AA or 40 mg QD was on average 3 to 4 bpm, and was smaller than that observed in the placebo or single dose moxifloxacin 400 mg group. This mild heart rate reduction was not considered clinically significant. The baseline-adjusted, time-matched differences between active treatment and placebo for QTc intervals using QTcNi (Linear) correction method are summarized in the table below. The upper bound of the 2-sided 90% CI around the LS mean difference from placebo for baseline-adjusted QTcNi (Linear) did not exceed 10 ms at any time point after administration of Lu AA mg or 40 mg QD; values ranged from 3.0 to 4.9 ms for Lu AA21004
7 10 mg and 5.6 to 8.4 ms for the supratherapeutic dose of Lu AA mg. The lower bound of the 2-sided 90% CI around the LS mean difference from placebo for baseline-adjusted QTcNi (Linear) exceeded 5 ms from 2 to 4 hours postdose after administration of a single dose of moxifloxacin 400 mg on Day 14, thereby demonstrating assay sensitivity. Moxifloxacin 400 mg single ECG Lu AA mg QD vs Lu AA mg QD vs dose vs Placebo QTcNi Collection Placebo QTcNi (Linear) (ms) Placebo QTcNi (Linear) (ms) (Linear) (ms) Time Postdose LS Mean 90% CI for LS Mean 90% CI for LS Mean 90% CI for (hrs) Difference Difference Difference Difference Difference Difference Predose 0.4 (-3.1, 3.9) 4.9 (1.4, 8.4) 1.7 (-1.8, 5.2) (-3.9, 3.1) 4.0 (0.5, 7.5) 7.2 (3.7, 10.7) (-2.8, 4.2) 3.8 (0.3, 7.3) 10.1 (6.6, 13.6) (-2.5, 4.5) 3.8 (0.3, 7.3) 11.0 (7.5, 14.6) (-2.1, 4.9) 4.4 (0.9, 7.9) 10.6 (7.1, 14.1) (-3.0, 4.0) 3.1 (-0.4, 6.6) 7.6 (4.1, 11.1) (-2.7, 4.3) 3.2 (-0.3, 6.7) 7.8 (4.3, 11.3) (-3.0, 4.0) 2.2 (-1.3, 5.7) 6.8 (3.3, 10.3) (-3.9, 3.1) 2.4 (-1.1, 5.9) 5.6 (2.1, 9.1) (-3.5, 3.5) 2.1 (-1.4, 5.6) 6.1 (2.6, 9.6) (-3.2, 3.8) 3.8 (0.3, 7.3) 7.9 (4.4, 11.4) (-2.2, 4.8) 4.4 (0.9, 7.9) 6.0 (2.5, 9.5) (-3.8, 3.2) 3.3 (-0.2, 6.8) 6.2 (2.7, 9.7) (-4.1, 3.0) 4.4 (0.9, 7.9) 5.6 (2.1, 9.1) Note: Statistical model used was a mixed effects model with treatment, time, treatment-by-time interaction as fixed effects, baseline QT/QTc as a covariate and repeated measure analysis with AR(1) covariance structure. The results of the primary endpoint of QTcNi (Linear) and the secondary endpoints of QTcF, QTcFm, and QTcB as well as from the post hoc analysis using QTcNi (Nonlinear) were consistent, and they indicated that Lu AA21004 had no clinically meaningful effect on cardiac repolarization based on the following observations: The upper bound of the 2-sided 90% CI around the LS mean difference from placebo for baseline-adjusted QTcNi (Linear), QTcF, QTcB, QTcFm, and QTcNi (Nonlinear) did not exceed 10 ms at any time point after administration of Lu AA mg or 40 mg QD for 14 days. The lower bound of the 2-sided 90% CI around the LS mean difference from placebo for baseline-adjusted QTcNi (Linear), QTcF, QTcB, QTcFm, and QTcNi (Nonlinear) exceeded 5 ms at at least 3 times points between 1 to 6 hours after administration of a single dose of moxifloxacin 400 mg on Day 14. The peak and time curve of the effect were consistent with those observed in similar thorough QT (TQT) studies in healthy volunteers and the study s ability to capture a small QT prolongation could thereby be demonstrated in compliance with International Conference on Harmonisation E14 guidance. Summary of ECG Outlier Events No notable treatment-related differences in the proportion of subjects with predefined outlier events for QTcNi (Linear), QTcF, QTcB, QTcFm, QTcNi (Nonlinear) were observed.
8 No clear treatment-related differences in the proportion of subjects with predefined outlier events for PR interval, QRS duration, or heart rate were noted. No positive U-waves were reported during the study. The percentage of subjects with T-wave morphology described as inverted, biphasic, and flat was small and equally distributed among all treatment groups at Baseline and after 14 days of dosing. Pharmacokinetic Results: The pharmacokinetic results for Lu AA21004 and its metabolites Lu AA34443 and Lu AA39835 were consistent with those observed in previous studies (see table below). Analyte Parameter (units) (a) n (b) Lu AA mg N=82 Arithmetic Mean (%CV) Geometric Mean n (b) Lu AA mg N=82 Arithmetic Mean (%CV) Geometric Mean Lu AA21004 AUC(0-24) (ng hr/ml) (46.04) (33.65) Cmax (ng/ml) (44.36) (35.19) Cmin (0) (ng/ml) (47.20) (38.25) --- Tmax (hr) (c) (0.00, 16.10) (4.10, 23.60) --- T1/2 (hr) (47.93) (36.19) --- CL/F (L/hr) (40.52) (33.97) --- Vss/F (L) (26.50) (18.54) --- Lu AA34443 AUC(0-24) (ng hr/ml) (36.84) (27.11) Cmax (ng/ml) (43.70) (32.57) Cmin (0) (ng/ml) (35.17) (28.64) --- Tmax (hr) (c) (3.10, 16.10) (3.10, 8.10) --- T1/2 (hr) (43.63) (33.90) --- Lu AA39835 AUC(0-24) (ng hr/ml) (29.66) (26.08) Cmax (ng/ml) (33.98) (27.09) 2.38 Cmin (0) (ng/ml) (27.86) (30.99) --- Tmax (hr) (c) (0.00, 16.10) (3.10, 12.10) --- T1/2 (hr) (40.94) (36.85) =not applicable, AUC(0-24)=area under the plasma concentration-time curve from time 0 to 24 hours, CV=coefficient of variance. (a) All PK parameters are presented for Day 14. (b) Several subjects did not have a complete dataset for specific pharmacokinetic parameters of at least 1 of the analytes Lu AA21004, Lu AA34443, and Lu AA (c) Tmax is presented as median (minimum, maximum).
9 The pharmacokinetic results for moxifloxacin were also consistent with those observed in previous similar studies (see table below). Parameter (units) Placebo/Moxifloxacin 400 mg N=82 Arithmetic n Mean (%CV) AUC(0-24) (ng hr/ml) (14) Cmax (ng/ml) (16) 1682 Tmax (hr) (a) (1.10, 5.10) --- T1/2 (hr) (26.08) =not applicable. (a) Tmax is presented as median (minimum, maximum). Geometric Mean Safety Results: Overall, 238 subjects (70.0%) experienced at least 1 treatment-emergent adverse event during the study. The incidence of subjects experiencing adverse events was highest for the Lu AA mg group (74.1%), 70.6% for the Lu AA mg group, 68.2% for the placebo only group, and 67.1% for the placebo/moxifloxacin group. One subject in the Lu AA mg treatment group experienced a treatment-emergent adverse event considered severe; all other treatment-emergent adverse events were considered mild or moderate in intensity. A total of 98 subjects (28.8%) experienced treatment-emergent adverse events considered at most possibly related to the study drug (22.4% placebo only, 31.8% Lu AA mg, 40.0% Lu AA mg, and 21.2% placebo/moxifloxacin) and 14 subjects (4.1%) experienced treatment-emergent adverse events considered probably related to study drug (3.5% placebo only, 4.7% Lu AA mg, 5.9% Lu AA mg, and 2.4% placebo/moxifloxacin). Eight subjects (2.4%), 2 in each treatment group experienced treatment-emergent adverse events that led to study drug discontinuation. There were no deaths or other SAEs during this study. The most common adverse event during the study was contact dermatitis (42.9% of subjects overall), occurring with similar incidence across the 4 treatment groups, as a reaction to the application of the electrodes during the ECG procedure. The most frequent drug related adverse events (in greater than 10 subjects overall) were, in decreasing order of incidence: headache, diarrhea, nausea, increased blood pressure, sinus tachycardia, and dizziness. The incidence of these adverse events was generally higher for the Lu AA21004 supratherapeutic dose (40 mg) compared with the other 3 treatment groups. Four Lu AA21004-treated subjects (2 Lu AA mg and 2 Lu AA mg) experienced single episodes of vasovagal syncope, which the investigator assessed as nonserious and secondary to vasomotor instability rather than to hemodynamically significant arrhythmias. Two cases were directly associated with venipuncture; the triggering event was not identified in the other 2 cases. For one of the 4 subjects (Lu AA mg treatment group), the adverse event of vasovagal syncope (considered severe and possibly related to study drug) led to study drug discontinuation; the subject s treatment was unblinded. Several subjects had clinical laboratory values meeting the potentially clinically significant criteria, but none of them were considered as adverse events or led to study drug discontinuation. One subject in the placebo/moxifloxacin experienced an adverse event of increased alanine aminotransferase (ALT) (104 IU/L on Day 14), however this elevation was not considered potentially clinically significant; the subject recovered (33 IU/L on Day 28) and completed the study as planned.
10 Several subjects had vital sign or ECG parameters measurements that met the criteria for being potentially clinically significant. Seventeen subjects (4 placebo only, 4 Lu AA mg, 6 Lu AA mg, and 3 placebo/moxifloxacin) experienced adverse events of increased blood pressure and for 2 of these subjects (from the placebo only and Lu AA mg treatment groups) the events led to study drug discontinuation. Additionally, 1 subject from the placebo/moxifloxacin treatment group experienced an adverse event of orthostatic hypotension that resulted in study drug discontinuation. Two subjects experienced ECG-related adverse events in the system organ class (SOC) of investigations, namely ECG T-wave inversion (in a Lu AA mg-treated subject) and ECG St-T change (in a placebo/moxifloxacintreated subject); both completed the study. CONCLUSIONS: In this TQT study, administration of Lu AA or 40 mg QD for 14 days to healthy male subjects had no clinically significant effect on cardiac repolarization. Administration of Lu AA or 40 mg QD for 14 days was well tolerated in healthy male subjects in this study. Date of Report: 15 July 2010
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;
The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More informationSponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationFor Discussion Purposes Only
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 Step 1 Draft 2 (July 17, 2003) Draft 3 (November 12, 2003), Draft 4 (June 10, 2004)
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Vfend /Voriconazole
More informationICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS.
European Medicines Agency London, 25 May 2005 CHMP/ICH/2/04 ICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS ICH Step 4 NOTE FOR
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationGuidance for Industry
Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs U.S. Department of Health and Human Services Food and Drug Administration
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
2. SYNOPSIS Title of Study: An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of and a Single Dose of Rosuvastatin (Crestor ), to Assess the Dose Proportionality of,
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBU
CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate
More informationSummary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ
CT Registry ID#4668 Page 1 Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ Date summary approved by Lilly: 09 August 2005 Title of Study: Safety and Efficacy of Atomoxetine or Atomoxetine Plus
More informationshort-term safety and tolerability of coadministration of ETR or DRV/rtv and artemether/lumefantrine in healthy subjects.
SYNOPSIS Issue Date: 6 March 2012 Name of Sponsor/Company Janssen EMEA Medical Affairs Name of Finished Product INTELENCE ; PREZISTA Name of Active Ingredient(s) etravirine (ETR, also known as TMC125);
More informationIQ-CSRC PROSPECTIVE STUDY RESULTS. Steve Riley, PharmD, PhD IQ-CSRC meeting December 12, 2014
IQ-CSRC PROSPECTIVE STUDY RESULTS Steve Riley, PharmD, PhD IQ-CSRC meeting December 12, 2014 IQ-CSRC prospective study - Design 20 male and female healthy subjects 3 treatment periods 9 subjects were to
More informationIntravenous Conivaptan: Effects on the QTc Interval and Other Electrocardiographic Parameters in Healthy Volunteers
Advances in Therapy Volume 24 No. 2 March/April 2007 Intravenous Conivaptan: Effects on the QTc Interval and Other Electrocardiographic Parameters in Healthy Volunteers Kenneth C. Lasseter, MD Stacy C.
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationSYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22
SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationSponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationData Quality in Small QTc Studies. Marek Malik, London
Data Quality in Small QTc Studies Marek Malik, London marek.malik@btinternet.com marek.malik@imperial.ac.uk Data Quality in Small QTc Studies DISCLAIMER Views and opinions presented are only my own Data
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: ABT-639 Name of Active Ingredient: ABT-639 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationIndustry Experience of the Concentration-QTc Relationship in Phase 1 Studies. Corina Dota, AstraZeneca
Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies Corina Dota, AstraZeneca CSRC-2 th February 2012 ICH E14 2.2.5 Alternative Strategies to Assess QT/QTc Interval Effects Alternatives
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationStudy No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationProduct: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670
Page 2 of 670 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C Name of Finished Product: Cinacalcet hydrochloride (Sensipar, Mimpara ) Name of ctive Ingredient: cinacalcet (cinacalcet hydrochloride
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPacing in Drug Testing
ISHNE International Society for Holter and Noninvasive Electrocardiology 1 st Worldwide Internet Symposium on Drug- Induced QT Prolongation October 1-15, 1 15, 2007 Pacing in Drug Testing I Savelieva,
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationIQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs
IQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs Nenad Sarapa, MD IQ-CSRC meeting, Silver Spring, MD 12 December 2014 Background SAD studies can reliably assess QTc prolongation if proper
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationPrincipal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan
Page 1 APPENDIX 9: ZRHM-PK-05-JP CLINICAL STUDY SUMMARY The study was conducted in Japan from August to November 2013. Principles as defined in International Conference on Harmonization (ICH) Good Clinical
More informationTreatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationDesign and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience
Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience Dr. Manfred Wargenau, Institute, Düsseldorf OVERVIEW Clinical background The ICH E14 guideline / review
More informationSYNOPSIS. Issue Date: 31 July 2013
SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003
More informationIQ/CSRC Study Waveform Sharing Program
IQ/CSRC Study Waveform Sharing Program Presentation for CSRC members August 26, 2015 Borje Darpo, icardiac Cindy Green, DCRI Georg Ferber, Independent Brian Smith, icardiac Jean-Philippe Couderc, THEW
More informationQT QT Study Design and Statistical Evaluation of QT Prolongation Introduction and QT Interval Correction
QT QT Study Design and Statistical Evaluation of QT Prolongation Introduction and QT Interval Correction Yasushi Orihashi Clinical Data and Biostatistics Department, Daiichi Sankyo Co., Ltd. email: orihashi.yasushi.c2@daiichisankyo.co.jp
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. International co-ordinating investigator Redacted
Drug product: Drug substance(s): AZD6140 Document No.: D5130C00002 Edition No.: 01 Study code: D5130C00002 Date: 12 October 2005 SYNOPSIS A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLack of an Effect of Standard and Supratherapeutic Doses of Linezolid on QTc Interval Prolongation
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2011, p. 4302 4307 Vol. 55, No. 9 0066-4804/11/$12.00 doi:10.1128/aac.01723-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Lack
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0145. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More informationSYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.
Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationJapanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information